148541-70-2

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 5-FLUOROPYRIDINE-2-CARBOXYLATE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of compounds with significant biological activity. Its unique structure allows for the creation of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, ETHYL 5-FLUOROPYRIDINE-2-CARBOXYLATE serves as a crucial building block in the synthesis of agrochemicals, aiding in the production of compounds designed to protect crops and enhance agricultural productivity.
Used in Research and Development:
ETHYL 5-FLUOROPYRIDINE-2-CARBOXYLATE is utilized as a valuable compound in research and development applications, where its unique properties are explored for potential uses in creating new chemical entities and understanding their interactions with biological systems.

InChI:InChI=1/C8H8FNO2/c1-2-12-8(11)7-4-3-6(9)5-10-7/h3-5H,2H2,1H3

Upstream product

• 107504-08-5 5-fluoropicolinic acid 
• 64-17-5 ethanol 
• 41404-58-4 2-bromo-5-fluoropyridine 
• 201230-82-2 carbon monoxide 

Downstream Products

• 1149752-51-1 N-[(1R)-1-(5-fluoropyridin-2-yl)ethyl]-2-methylropane-2-sulfinamide 
• 1310809-41-6 C₂₅H₃₀N₆O₆ 
• 1310807-58-9 3-{[6-(hydrazinocarbonyl)pyridin-3-yl]oxy}-5-isopropoxy-N-(1-methyl-1H-pyrazol-3-yl)benzamide 
• 1310809-56-3 ethyl 5-(5-{3-isopropoxy-5-[(1-methyl-1H-pyrazol-3-yl)carbamoyl]phenoxy}pyridin-2-yl)-1,3,4-oxadiazole-2-carboxylate 
• 1310807-59-0 ethyl {2-[(5-{3-isopropoxy-5-[(1-methyl-1H-pyrazol-3-yl)carbamoyl]phenoxy}pyridin-2-yl)carbonyl]hydrazino}(oxo)acetate 
• 1310807-57-8 5-{3-isopropoxy-5-[(1-methyl-1H-pyrazol-3-yl)carbamoyl]phenoxy}pyridine-2-carboxylic acid 
• 1310805-69-6 5-(5-{3-isopropoxy-5-[(1-methyl-1H-pyrazol-3-yl)carbamoyl]phenoxy}pyridin-2-yl)-N-methyl-1,3,4-oxadiazole-2-carboxamide 
• 802325-29-7 5-fluoro-2-hydroxylmethylpyridine 
• 31181-88-1 5-fluoropicolinaldehyde 

Relevant academic research and scientific papers

SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF

The present invention relates to a sulfoximine compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.

P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor s

P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X

P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor s

OXIME COMPOUNDS AND THE USE THEREOF

The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO2, CRsu

IMIDAZOPYRIDINE COMPOUND

The present invention provides an imidazopyridine compound represented by formula (I), wherein R1 and R2 each independently represent a C1-6 alkyl group et al; R3 and R4 each independently represent a hydrogen atom, a methyl et al; Ar1 is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar2 represents an aromatic carbocyclic group, or an aromatic heterocyclic group; W represents -(CH2)m et al, and m indicates an integer of from 0 to 10. This compound acts as a melanin concentrating hormone receptor antagonist, and is useful as treating agents for obesity.

NEW COMPOUNDS

The present invention relates to new compounds of formula I, wherein P Q X1 X2 X3 X4 X5 R R1 R2 R3 R4R5 G M1 M2 M3 m and n are defined as in formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

A novel and versatile access to fluorinated carbo- and heterocyclic compounds employing electron-rich fluorodienes as cycloaddition components

The readily accessible 2-fluoro-1-trimethylsilyloxy-1,3-dienes undergo Diels-Alder type cycloaddition with a variety of dienophiles under mild conditions. In this way, fluoro-2-cyclohexenols, fluoro-2,5-dihydropyranols, fluoro-2,5-dihydro-2-pyridinols, fl